Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.

@article{Nordigrden2011IrreversiblePI,
  title={Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.},
  author={Amanda Nordig{\aa}rden and Jenny Zetterblad and Cecilia Trinks and Henrik Gr{\'e}en and Pernilla Eliasson and Pia Druid and Kourosh Lotfi and Lars R{\"o}nnstrand and Thomas Walz and Jan-Ingvar J{\"o}nsson},
  journal={British journal of haematology},
  year={2011},
  volume={155 2},
  pages={198-208}
}
Recent findings have indicated that tyrosine kinase inhibitors (TKIs) targeting the ERBB receptor family display anti-leukaemic effects, despite the lack of receptor expression on human leukaemic cells. The occurrence of activating mutations in the gene encoding FMS-like tyrosine kinase 3 (FLT3) in patients with acute myeloid leukaemia (AML) has rendered inhibition of this receptor a promising therapeutic target. Due to possibility of cross-reactivity, we investigated the effect of the… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…